Roles of Interleukin-17 in Endothelial Cells Endothelial cell (EC) activation and inflammation significantly contribute to vascular inflammation. In addition to being stimulated by proinflammatory/proatherogenic risk factors such as hyperlipidemia, ECs are also the target of proinflammatory cytokines. Since 2003, a new lineage of CD4+RORt+ (retinoid-related orphan receptor) T cells has been defined by its production of proinflammatory cytokine interleukin-17 (IL-17) and hence named T-helper 17 (Th17) cells. These cells are found to play an essential role in promoting autoimmune diseases and inflammation. However, an important question of whether molecular signaling pathway of IL-17 plays a critical role in EC activation remains to be answered. Therefore, the goal of this proposal is to examine a central hypothesis that IL-17, induced by hyperlipidemia, plays a critical role in EC activation. The publications from our labs and others'as well as our preliminary data support this hypothesis: (i) IL-17 receptor A (IL-17RA) is expressed in aortic ECs. High levels of IL-17 receptor C (IL-17RC) expression are observed in ECs, suggesting the functional receptor complex IL-17RA/C is expressed in ECs and is able to initiate signaling in response to IL-17 stimulation;(ii) IL-17 is upregulated in human aortic ECs exposed to disturbed blood flow, an EC activation condition, suggesting that ECs can be further stimulated by IL-17 via an autocrine mechanism;(iii) Plasma IL-17 level and Th17 cells are elevated in apolipoprotein E deficient (ApoE-/- ) atherogenic mice, suggesting that hyperlipidemia makes more IL-17 available to stimulate ECs;and (iv) Inhibition of IL-17 suppresses inflammation. Inhibition of IL-17 with antibodies attenuates vascular inflammation in ApoE-/- mice, suggesting that IL-17 plays a critical role in vascular inflammation. We have a long standing interest in studying immune regulation of endothelial activation and vascular inflammation. Therefore, we have the expertise to complete this project. This goal will be pursued through the execution of the following specific aims: (1) To determine whether IL-17 signaling pathway is upregulated in aortic ECs in ApoE-/- mice;(2) To determine whether IL-17-induced human EC activation is mechanistically dependent on its upregulation of proinflammatory cytokines and chemokines;(3) To determine whether IL-17 gene depletion inhibits EC activation in IL-17-/-/ApoE-/- mice. This project is significant since success of this project may lead to future development of new therapeutics for treating EC activation/inflammation.

Public Health Relevance

There is increasing evidence that vascular endothelial cell (ECs) activation and inflammation significantly contribute to the development of vascular inflammation. However, the importance of newly characterized cytokine interleukin-17 (IL-17) signaling plays a critical role in initiating EC activation and inflammation remains poorly defined. The proposed studies will provide better understanding whether the elucidation of IL-17 molecular signaling in EC activation and inflammation can lead to the development of new therapeutics for treating vascular cell inflammation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL108910-02
Application #
8308370
Study Section
Special Emphasis Panel (ZRG1-VH-F (02))
Program Officer
Hasan, Ahmed AK
Project Start
2011-08-01
Project End
2016-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
2
Fiscal Year
2012
Total Cost
$382,500
Indirect Cost
$132,500
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Lopez-Pastrana, Jahaira; Shao, Ying; Chernaya, Valeria et al. (2015) Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells. Transl Res 165:221-40
Tan, Hongmei; Shi, Chengwei; Jiang, Xiaohua et al. (2014) Hyperhomocysteinemia promotes vascular remodeling in vein graph in mice. Front Biosci (Landmark Ed) 19:958-66
Yang, Jiyeon; Zhang, Lixiao; Yu, Caijia et al. (2014) Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2:1
Meng, Shu; Ciment, Stephen; Jan, Michael et al. (2013) Homocysteine induces inflammatory transcriptional signaling in monocytes. Front Biosci (Landmark Ed) 18:685-95
Huang, Xiao; Gong, Ren; Li, Xinyuan et al. (2013) Identification of novel pretranslational regulatory mechanisms for NF-*B activation. J Biol Chem 288:15628-40
Mai, Jietang; Virtue, Anthony; Shen, Jerry et al. (2013) An evolving new paradigm: endothelial cells--conditional innate immune cells. J Hematol Oncol 6:61
Li, Xinyuan; Fang, Pu; Mai, Jietang et al. (2013) Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol 6:19
Yin, Ying; Pastrana, Jahaira Lopez; Li, Xinyuan et al. (2013) Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci (Landmark Ed) 18:638-49
Mai, Jietang; Virtue, Anthony; Maley, Erin et al. (2012) MicroRNAs and other mechanisms regulate interleukin-17 cytokines and receptors. Front Biosci (Elite Ed) 4:1478-95
Li, Xinyuan; Mai, Jietang; Virtue, Anthony et al. (2012) IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines. PLoS One 7:e33628